NCT05665491 Role of Parent Interpretation Bias in the Transmission of Anxiety to Children
| NCT ID | NCT05665491 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mclean Hospital |
| Condition | Anxiety |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2023-07-28 |
| Primary Completion | 2027-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 300 participants in total. It began in 2023-07-28 with a primary completion date of 2027-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Approximately 30% of children will experience an anxiety disorder, making anxiety the most common mental health problem among children in the United States. However, few children receive treatment and even our most effective anxiety treatments leave up to half of children in need of additional intervention. Despite the well-established role of parent anxiety in transmitting and maintaining child anxiety, the lack of data on specific parent mechanisms underlying the intergenerational transmission of anxiety is a critical barrier to informing novel targets of personalized treatments. Consistent with NIMH's Strategic Plan, Objective 2.2 to understand risk factors and behavioral indicators of mental illness across the lifespan and to identify novel intervention targets based on knowledge of psychological mechanisms, the current study focuses on interpretation bias, the tendency to perceive threat in ambiguous situations. The overall objective of this project is to empirically test a theoretical model of the intergenerational transmission of anxiety focused on parent interpretation bias as a root cause. Our specific aims are to test theorized effects of parent interpretation bias on (1) parent behavior and (2) child interpretation bias and (3) evaluate potential moderators to refine theories of intergenerational transmission of anxiety and inform future personalized interventions. Our central hypothesis is that parent interpretation bias influences child interpretation bias through its effects on maladaptive, anxiety-promoting parenting behaviors, such as accommodation and modeling of avoidant coping. To test this hypothesis, we will randomize 300 parents of children ages 7-12 to complete four weeks of a smartphone delivered interpretation bias manipulation vs. a self-assessment smartphone app condition. The interpretation bias intervention teaches parents to interpret ambiguous situations in a non-threatening manner via quick, repeated practice and corrective feedback. Before and after completing their randomly assigned condition, parent-child dyads will complete self-report and behavioral tasks designed to elicit anxiety-promoting behaviors from parents depending upon their interpretation of the ambiguous situation (speech and puzzle tasks). Parents will also complete Ecological Momentary Assessment (EMA) of parenting behaviors to capture the time course of effects. Finally, we will examine downstream effects of the interpretation manipulation on child interpretation bias at pre- and post- visits. We will test moderators (e.g., parent anxiety and gender) to refine theories of intergenerational transmission of anxiety and inform future personalized interventions. The long-term goal of this work is to inform personalized, mechanism-focused interventions to improve mental health outcomes for anxious children and their parents. Future studies will translate knowledge gained from this project into a scalable treatment that can be implemented entirely remotely via smartphone thereby increasing access to care
Eligibility Criteria
Inclusion criteria for parent participants are: 1. Must have an ability to speak and understand English sufficiently to complete assessments 2. At least minimal anxiety severity (GAD-7 score \> 5) 3. At least a minimal level of interpretation bias (WSAP overall accuracy less than 70%) 4. No current psychiatric symptoms that would interfere with the individual's ability to provide consent or complete the research procedures 5. If receiving treatment, stable on medications or psychotherapy for 8 weeks 6. No severe suicidal ideation (PHQ-9 item 9 \> 1) 7. Own iOS or Android smartphone 8. Shared or full custody of child (for EMA assessment of parenting behaviors) Inclusion criteria for child participants are: 1. Age 7 to 12 2. Must have an ability to speak and understand English sufficiently to complete assessments 3. No diagnosis of intellectual disability or autism spectrum disorder (per parent or clinician report) 4. No current psychiatric symptoms that would prevent informed consent or understanding of research procedures 5. Wechsler Abbreviated Scale of Intelligence (WASI) full-scale IQ equal to or greater than 80 to ensure understanding of study procedures 6. If receiving treatment, stable on medications or psychotherapy for 8 weeks 7. No severe suicidal ideation (PHQ-9 item 9 \> 1)
Contact & Investigator
Courtney Beard, PhD
PRINCIPAL INVESTIGATOR
Mclean Hospital
Frequently Asked Questions
Who can join the NCT05665491 clinical trial?
This trial is open to participants of all sexes, aged 7 Years or older, studying Anxiety. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05665491 currently recruiting?
Yes, NCT05665491 is actively recruiting participants. Contact the research team at cbeard@mclean.harvard.edu for enrollment information.
Where is the NCT05665491 trial being conducted?
This trial is being conducted at Belmont, United States.
Who is sponsoring the NCT05665491 clinical trial?
NCT05665491 is sponsored by Mclean Hospital. The principal investigator is Courtney Beard, PhD at Mclean Hospital. The trial plans to enroll 300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.